Vimpat 150mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Lacosamide

Available from:

UCB Pharma Ltd

ATC code:

N03AX18

INN (International Name):

Lacosamide

Dosage:

150mg

Pharmaceutical form:

Tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 04080100; GTIN: 5015313013277 5015313013284

Patient Information leaflet

1
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
VIMPAT 50 MG FILM-COATED TABLETS
VIMPAT 100 MG FILM-COATED TABLETS
VIMPAT 150 MG FILM-COATED TABLETS
VIMPAT 200 MG FILM-COATED TABLETS
lacosamide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Vimpat is and what it is used for
2.
What you need to know before you take Vimpat
3.
How to take Vimpat
4.
Possible side effects
5.
How to store Vimpat
6.
Contents of the pack and other information
1.
WHAT VIMPAT IS AND WHAT IT IS USED FOR
WHAT VIMPAT IS
Vimpat contains lacosamide. This belongs to a group of medicines
called “antiepileptic medicines”.
These medicines are used to treat epilepsy.
•
You have been given this medicine to lower the number of fits
(seizures) you have.
WHAT VIMPAT IS USED FOR
•
Vimpat is used in adults, adolescents and children aged 4 years and
older.
•
It is used to treat a certain type of epilepsy called “partial-onset
seizure with or without
secondary generalisation”.
•
In this type of epilepsy, fits first affect only one side of your
brain. However, these may then
spread to larger areas on both sides of your brain.
•
Vimpat may be used on its own or with other antiepileptic medicines.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VIMPAT
DO NOT TAKE VIMPAT
•
if you are allergic to lacosamide, or any of the other ingredients of
this medicine (listed in
section 6). If you are not sure whether you are allergic, please
discuss with your doctor.
•
if you have a certain type of heart beat problem called second-

Summary of Product characteristics

OBJECT 1
VIMPAT 50 MG FILM-COATED TABLETS
Summary of Product Characteristics Updated 14-Dec-2017 | UCB Pharma
Limited
1. Name of the medicinal product
Vimpat 50 mg film-coated tablets
Vimpat 100 mg film-coated tablets
Vimpat 150 mg film-coated tablets
Vimpat 200 mg film-coated tablets
2. Qualitative and quantitative composition
Vimpat 50 mg film-coated tablets
Each film-coated tablet contains 50 mg lacosamide.
Vimpat 100 mg film-coated tablets
Each film-coated tablet contains 100 mg lacosamide.
Vimpat 150 mg film-coated tablets
Each film-coated tablet contains 150 mg lacosamide.
Vimpat 200 mg film-coated tablets
Each film-coated tablet contains 200 mg lacosamide.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet
Vimpat 50 mg film-coated tablets
Pinkish, oval film-coated tablets with approximate dimensions of 10.4
mm x 4.9 mm, and debossed with
'SP' on one side and '50' on the other side.
Vimpat 100 mg film-coated tablets
Dark yellow, oval film-coated tablets with approximate dimensions of
13.2 mm x 6.1 mm, and debossed
with 'SP' on one side and '100' on the other side.
Vimpat 150 mg film-coated tablets
Salmon, oval film-coated tablets with approximate dimensions of 15.1
mm x 7.0 mm, and debossed with
'SP' on one side and '150' on the other side.
Vimpat 200 mg film-coated tablets
Blue, oval film-coated tablets with approximate dimensions of 16.6 mm
x 7.8 mm, and debossed with 'SP'
on one side and '200' on the other side.
4. Clinical particulars
4.1 Therapeutic indications
Vimpat is indicated as monotherapy and adjunctive therapy in the
treatment of partial-onset seizures with
or without secondary generalisation in adults, adolescents and
children from 4 years of age with epilepsy.
4.2 Posology and method of administration
Posology
Lacosamide must be taken twice a day (usually once in the morning and
once in the evening).
Lacosamide may be taken with or without food.
If a dose is missed, the patient should be instructed to take the
missed dose immediately, and then to take